Haneen Shalabi, Ashley Koegel, Anusha Ponduri, Haiying Qin, Dalia Salem, Maryalice Stetler-Stevenson, Constance Yuan, Bonnie Yates, Cindy Delbrook, Mignon Loh, Terry J. Fry, Nirali N. Shah
{"title":"病例报告:BITE对CAR - T细胞扩增的影响","authors":"Haneen Shalabi, Ashley Koegel, Anusha Ponduri, Haiying Qin, Dalia Salem, Maryalice Stetler-Stevenson, Constance Yuan, Bonnie Yates, Cindy Delbrook, Mignon Loh, Terry J. Fry, Nirali N. Shah","doi":"10.1002/acg2.50","DOIUrl":null,"url":null,"abstract":"<p>Targeted immunotherapeutic approaches have become an attractive, novel therapy in the treatment of chemotherapy resistant or relapsed high-risk acute lymphoblastic leukemia (ALL). Many of these therapies, chimeric antigen receptor (CAR) T cells, and bispecific T-cell engagers (BiTE) in particular, rely on surface expression of the antigen for activity and efficacy. As such, antigen loss is a growing problem in this relapsed population. We present a case of relapsed, refractory B-ALL that has immunophenotypic variability in the leukemia blasts in response to the sequential targeted immunotherapies received. This case additionally describes a bolstered CAR-T cell expansion after the patient received subsequent blinatumomab therapy, suggesting a potential strategy for utilization of multiagent immunotherapies to have synergistic approaches to eradicate disease and prolong remission in patients with relapsed hematologic malignancies (Anti-CD22 chimeric receptor T cells in pediatric and young adult patients with recurrent or relapsed CD22-expressing B-cell malignancies. clinicaltrials.gov NCT02315612).</p>","PeriodicalId":72084,"journal":{"name":"Advances in cell and gene therapy","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2019-02-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1002/acg2.50","citationCount":"7","resultStr":"{\"title\":\"Case report: Impact of BITE on CAR-T cell expansion\",\"authors\":\"Haneen Shalabi, Ashley Koegel, Anusha Ponduri, Haiying Qin, Dalia Salem, Maryalice Stetler-Stevenson, Constance Yuan, Bonnie Yates, Cindy Delbrook, Mignon Loh, Terry J. Fry, Nirali N. Shah\",\"doi\":\"10.1002/acg2.50\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p>Targeted immunotherapeutic approaches have become an attractive, novel therapy in the treatment of chemotherapy resistant or relapsed high-risk acute lymphoblastic leukemia (ALL). Many of these therapies, chimeric antigen receptor (CAR) T cells, and bispecific T-cell engagers (BiTE) in particular, rely on surface expression of the antigen for activity and efficacy. As such, antigen loss is a growing problem in this relapsed population. We present a case of relapsed, refractory B-ALL that has immunophenotypic variability in the leukemia blasts in response to the sequential targeted immunotherapies received. This case additionally describes a bolstered CAR-T cell expansion after the patient received subsequent blinatumomab therapy, suggesting a potential strategy for utilization of multiagent immunotherapies to have synergistic approaches to eradicate disease and prolong remission in patients with relapsed hematologic malignancies (Anti-CD22 chimeric receptor T cells in pediatric and young adult patients with recurrent or relapsed CD22-expressing B-cell malignancies. clinicaltrials.gov NCT02315612).</p>\",\"PeriodicalId\":72084,\"journal\":{\"name\":\"Advances in cell and gene therapy\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2019-02-04\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1002/acg2.50\",\"citationCount\":\"7\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Advances in cell and gene therapy\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1002/acg2.50\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Advances in cell and gene therapy","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/acg2.50","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Case report: Impact of BITE on CAR-T cell expansion
Targeted immunotherapeutic approaches have become an attractive, novel therapy in the treatment of chemotherapy resistant or relapsed high-risk acute lymphoblastic leukemia (ALL). Many of these therapies, chimeric antigen receptor (CAR) T cells, and bispecific T-cell engagers (BiTE) in particular, rely on surface expression of the antigen for activity and efficacy. As such, antigen loss is a growing problem in this relapsed population. We present a case of relapsed, refractory B-ALL that has immunophenotypic variability in the leukemia blasts in response to the sequential targeted immunotherapies received. This case additionally describes a bolstered CAR-T cell expansion after the patient received subsequent blinatumomab therapy, suggesting a potential strategy for utilization of multiagent immunotherapies to have synergistic approaches to eradicate disease and prolong remission in patients with relapsed hematologic malignancies (Anti-CD22 chimeric receptor T cells in pediatric and young adult patients with recurrent or relapsed CD22-expressing B-cell malignancies. clinicaltrials.gov NCT02315612).